Kyorin pays $12m upfront for Japanese rights to Edesa's TLR4 lung drug

Edesa Biotech has handed Kyorin Pharmaceutical exclusive rights to develop and sell paridiprubart in Japan for acute respiratory distress syndrome (ARDS), in an agreement signed on 9 November 2026. Paridiprubart is an antibody directed at TLR4.

For Edesa, the financial terms are weighted towards the future. It receives $12m upfront, and is eligible for milestone payments of up to about $134m, which together put the headline value of the arrangement above $140m. Only the upfront sum is certain. The milestone money depends on events the announcement does not specify. Edesa would also earn tiered double-digit royalties on Japanese sales.

Edesa will manufacture and supply the product to Kyorin, so it keeps a role in the commercial chain rather than simply handing over the programme. The announcement gives no detail on supply pricing or quality arrangements.

Kyorin also holds a right of first negotiation on paridiprubart in acute kidney injury. No terms for any such deal were disclosed, and the right does not commit either company to one.

The agreement does not alter the drug's regulatory position. Paridiprubart has no Japanese approval and no National Health Insurance price, so any sales, and therefore any royalties, depend on later regulatory and reimbursement decisions.